Dr. Alessandro Armuzzi
Claim this profileIstituto Clinico Humanitas
Clinical Trials Alessandro Armuzzi is currently running
Obefazimod
for Crohn's Disease
This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies. The primary objective for the 48-Week Extension Phase is to evaluate the safety and tolerability of obefazimod compared with placebo in subjects who are enrolled in the Extension Phase.
Recruiting
0 awards
Phase 2
4 criteria
TAK-279
for Ulcerative Colitis
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study, participants will visit their study clinic several times.
Recruiting
0 awards
Phase 2
1 criteria
More about Alessandro Armuzzi
Clinical Trial Related
1 year of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Alessandro Armuzzi has experience with
- Mirikizumab
- TAK-279
- ABX464
- Placebo
- BMS-986165
- Obefazimod
Breakdown of trials Alessandro Armuzzi has run
Ulcerative Colitis
Crohn's Disease
Colitis
Inflammatory Bowel Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alessandro Armuzzi specialize in?
Alessandro Armuzzi focuses on Ulcerative Colitis and Crohn's Disease. In particular, much of their work with Ulcerative Colitis has involved treating patients, or patients who are undergoing treatment.
Is Alessandro Armuzzi currently recruiting for clinical trials?
Yes, Alessandro Armuzzi is currently recruiting for 3 clinical trials in Rozzano Milano. If you're interested in participating, you should apply.
Are there any treatments that Alessandro Armuzzi has studied deeply?
Yes, Alessandro Armuzzi has studied treatments such as Mirikizumab, TAK-279, ABX464.
What is the best way to schedule an appointment with Alessandro Armuzzi?
Apply for one of the trials that Alessandro Armuzzi is conducting.
What is the office address of Alessandro Armuzzi?
The office of Alessandro Armuzzi is located at: Istituto Clinico Humanitas, Rozzano, Milano 20089 Italy. This is the address for their practice at the Istituto Clinico Humanitas.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.